Research graph
References from Efficacy and Safety of Flecainide Versus Amiodarone for the Cardioversion of paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease without evidence of residual ischemia: The FLECA-ED Randomized Clinical Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
10.1093/eurheartj/ehae176 · 2024 · External reference
Mortality and morbidity in patients receiving encainide, flecainide, or placebo
1991 · External reference
Pharmacological Cardioversion of Atrial Tachyarrhythmias Using Single High-Dose Oral Amiodarone: A Systematic Review and Meta-Analysis
10.1161/circep.121.010321 · 2021 · External reference
Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED)
10.3390/jcm12123961 · 2023 · External reference
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
10.1093/eurheartj/ehz425 · 2020 · External reference
Unresolved reference
2020 · External reference
Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis
10.1007/s10557-020-07127-1 · 2021 · External reference
10.1002/9781118458167
10.1002/9781118458167 · External reference
Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST)
10.1161/01.cir.90.6.2843 · 1994 · External reference
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial
10.1016/0002-9149(91)90308-8 · 1991 · External reference
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I
10.1136/hrt.74.6.631 · 1995 · External reference
Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study)
10.1016/s0002-9149(02)02867-9 · 2002 · External reference
Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort
10.1016/j.hrthm.2026.02.042 · 2026 · External reference
Flecainide in structural heart diseases: A contemporary reappraisal beyond the CAST
10.1016/j.hrthm.2025.08.034 · 2026 · External reference
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease
10.1016/j.jacep.2022.12.021 · 2023 · External reference
Expanding the indications for flecainide: Good idea or CAST reprise?
10.1016/j.hrthm.2025.09.030 · 2026 · External reference
Flecainide use before and after the Cardiac Arrhythmia Suppression Trial: A systematic review
10.1016/j.hrthm.2026.02.010 · 2026 · External reference
2026 HRS/PACES scientific statement on the use of antiarrhythmic drugs in understudied clinical scenarios
10.1016/j.hrthm.2026.07.012 · 2026 · External reference
Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study
10.1016/0735-1097(95)00595-1 · 1996 · External reference
Amiodarone versus placebo and class ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis
10.1016/s0735-1097(02)02705-5 · 2003 · External reference
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm
10.1016/s0002-9149(00)01128-0 · 2000 · External reference
Impact of emergency department management of atrial fibrillation on hospital charges
10.5811/westjem.2012.1.6893 · 2013 · External reference
